363 related articles for article (PubMed ID: 7887443)
21. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme.
Hayashi Y; Ueki K; Waha A; Wiestler OD; Louis DN; von Deimling A
Brain Pathol; 1997 Jul; 7(3):871-5. PubMed ID: 9217972
[TBL] [Abstract][Full Text] [Related]
22. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
23. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
[TBL] [Abstract][Full Text] [Related]
24. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia.
Iravani M; Dhat R; Price CM
Oncogene; 1997 Nov; 15(21):2609-14. PubMed ID: 9399648
[TBL] [Abstract][Full Text] [Related]
25. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
Farrell WE; Simpson DJ; Bicknell JE; Talbot AJ; Bates AS; Clayton RN
Cancer Res; 1997 Jul; 57(13):2703-9. PubMed ID: 9205080
[TBL] [Abstract][Full Text] [Related]
26. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Li YJ; Hoang-Xuan K; Delattre JY; Poisson M; Thomas G; Hamelin R
Oncogene; 1995 Aug; 11(3):597-600. PubMed ID: 7630644
[TBL] [Abstract][Full Text] [Related]
27. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia.
Zhou M; Gu L; Yeager AM; Findley HW
Pediatr Hematol Oncol; 1997; 14(2):141-50. PubMed ID: 9089742
[TBL] [Abstract][Full Text] [Related]
28. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Ogawa S; Hangaishi A; Miyawaki S; Hirosawa S; Miura Y; Takeyama K; Kamada N; Ohtake S; Uike N; Shimazaki C
Blood; 1995 Aug; 86(4):1548-56. PubMed ID: 7632963
[TBL] [Abstract][Full Text] [Related]
29. Alterations of CDKN2 (p16) in non-small cell lung cancer.
de Vos S; Miller CW; Takeuchi S; Gombart AF; Cho SK; Koeffler HP
Genes Chromosomes Cancer; 1995 Nov; 14(3):164-70. PubMed ID: 8589032
[TBL] [Abstract][Full Text] [Related]
30. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
31. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
Dreyling MH; Bohlander SK; Adeyanju MO; Olopade OI
Cancer Res; 1995 Mar; 55(5):984-8. PubMed ID: 7867008
[TBL] [Abstract][Full Text] [Related]
32. Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9.
Wu Q; Possati L; Montesi M; Gualandi F; Rimessi P; Morelli C; Trabanelli C; Barbanti-Brodano G
Int J Cancer; 1996 Mar; 65(6):840-6. PubMed ID: 8631601
[TBL] [Abstract][Full Text] [Related]
33. Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ
Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764
[TBL] [Abstract][Full Text] [Related]
34. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ
Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335
[TBL] [Abstract][Full Text] [Related]
35. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood.
Ohnishi H; Hanada R; Horibe K; Hongo T; Kawamura M; Naritaka S; Bessho F; Yanagisawa M; Nobori T; Yamamori S; Hayashi Y
Leukemia; 1996 Jul; 10(7):1104-10. PubMed ID: 8683987
[TBL] [Abstract][Full Text] [Related]
36. Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells.
Jagasia AA; Sher DA; Le Moine PJ; Kim DH; Moldwin RL; Smith SD; Diaz MO
Leukemia; 1996 Apr; 10(4):624-8. PubMed ID: 8618438
[TBL] [Abstract][Full Text] [Related]
37. CDKN2 (MTS1/p16INK4A) gene alterations in hematological malignancies.
Uchida T; Kinoshita T; Saito H; Hotta T
Leuk Lymphoma; 1997 Feb; 24(5-6):449-61. PubMed ID: 9086436
[TBL] [Abstract][Full Text] [Related]
38. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
39. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
40. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
